Vanda Pharmaceuticals Reports Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Vanda Pharmaceuticals (VNDA) Tops Q3 EPS by 6c, Revenues Beat
November 6, 2019 4:43 PM ESTVanda Pharmaceuticals (NASDAQ: VNDA) reported Q3 EPS of $0.13, $0.06 better than the analyst estimate of $0.07. Revenue for the quarter came in at $59.49 million versus the consensus estimate of $58.32 million.
"These results affirm Vanda's corporate strategy, and continue to demonstrate our ability to grow... More
